Ob/Gyn Medical News about Postmenopause letrozole Breast Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
Therapeutics and Clinical Risk Management, 09/14/09

Monnier A – The accepted strategies for adjuvant aromatase inhibitors (AIs) therapy include initial adjuvant treatment following surgery, switching and/or sequencing from prior tamoxifen, and extended adjuvant therapy following the full 5 years of tamoxifen treatment. Among the available AIs, letrozole has been evaluated in large, well–controlled, double–blind clinical trials in the initial adjuvant, extended adjuvant, and more recently, the sequential adjuvant settings. Letrozole is the most potent of the AIs and provides near complete suppression of plasma estrogens in PMW. Letrozole also significantly reduces the occurrence of early distant metastases, the most lethal type of recurrence event, which can lead to improved survival. Clinical comparisons of letrozole with both tamoxifen and placebo have also provided important long–term safety data on the use of AIs as adjuvant therapy in PMW with EBC. The weight of clinical evidence indicates that letrozole is a safe and effective option for adjuvant hormonal therapy across all three AI treatment settings.

<< Previous
Incidence and mortality of cardiovascular disease in...

Next >>
Development of an Instrument to Measure Adherence to Strength...

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
Journal of Clinical Oncology, 10/02/09 Relevance Score: 82%

Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Cancer Epidemiology, Biomarkers & Prevention, 10/23/09 Relevance Score: 81%

Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3N-EPIC Prospective Cohort Study
American Journal of Epidemiology, 10/22/09 Relevance Score: 81%

Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
Expert Review of Anticancer Therapy, 11/12/09 Relevance Score: 80%

Mammographic Screening and Risk Factors for Breast Cancer
American Journal of Epidemiology, 10/30/09 Relevance Score: 80%